PCRX vs AMPH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

PCRX

54.7
AI Score
VS
PCRX Wins

AMPH

50.6
AI Score

Investment Advisor Scores

PCRX

55score
Recommendation
HOLD

AMPH

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PCRX AMPH Winner
Revenue 177.38M 171.17M PCRX
Net Income 2.92M 6.42M AMPH
Net Margin 1.6% 3.8% AMPH
Operating Income 6.90M 13.63M AMPH
ROE 0.4% 0.8% AMPH
ROA 0.2% 0.4% AMPH
Total Assets 1.21B 1.65B AMPH
Cash 144.31M 170.94M AMPH
Current Ratio 4.73 3.85 PCRX
Free Cash Flow 22.96M 38.33M AMPH

Relative Price Performance (Last 90 Days)

PCRX 1M: +6.0% · 3M: +10.1% AMPH 1M: +3.0% · 3M: -7.6%

Current Technical Phase

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 64

RSI (14): 64.0 · Price: $26.92

AMPH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 55

RSI (14): 54.6 · Price: $20.22

Fundamentals Snapshot

Metric PCRX AMPH
Market Cap
Forward P/E 7.4 6.8
Trailing P/E 203.2 12.0
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 0.8% 0.5%
Operating Margin 0.0% 0.1%
EPS 0.13 1.66
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.